Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NCT01657461 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
DEVICE: Solitaire revascularization device

Sponsor

Medtronic Neurovascular Clinical Affairs